FORT LAUDERDALE, Fla., Feb. 23, 2017 /PRNewswire/ -- Viera BioScience Inc. announced today it will be presenting at the 2017 Academy of Regenerative Practices Conference at the Renaissance Hotel in Fort Lauderdale, Florida on February 25th at 3:25 PM. The talk, entitled, "Stimulation of Angiogenesis by Angiostem T Regulatory Cell", will be given by Thomas Ichim, Ph.D, President and CEO of Viera BioScience. In the presentation, preclinical efficacy and safety data of the AngioMune cord blood derived will be discussed, as well as outcomes in the first 5 patients treated.
"The AngioMune product has substantial potential as a tool for regenerative medicine given the ease of manufacturing, universal applicability and potential for superior biodistribution due to the smaller size of T regulatory cells compared to conventional stem cells," said Amit Patel, MS, MD, Head of Cardiothoracic Surgery at the University of Miami and Scientific Advisory Board member of Viera BioScience.
AngioMune is a cord blood derived product that has demonstrated ability to induce new blood vessel formation in animal models, a process called "angiogenesis." The market potential for angiogenesis stimulating products is in the billions of dollars due to potential for treatment of peripheral artery disease and coronary artery disease. Peripheral artery disease is estimated to have a market size in the U.S. of approximately $3 billion annually(1), and coronary artery disease of $12.2 billion(2).
"Having leveraged technology originating from the University of Utah, combined with our in-house advancements, we are proud to have advanced the AngioMune product from the bench to the bedside. I look forward to Dr. Ichim's presentation and announcement of our research, which has the potential to impact many patients who at present have no treatment options," said John Peck Jr., Chairman of Viera BioScience.
Event: 2017 Academy of Regenerative Practices Conference Presenter: Thomas Ichim, PhD, President and CEO of Viera BioScience: Stimulation of Angiogenesis by Angiostem T Regulatory Cells Where: Renaissance Hotel in Fort Lauderdale, Florida When: February 25th, 3:25 PM - 3:55 PM
1 http://www.businesswire.com/news/home/20101214006406/en/SAGE-GROUP-Reports-2010-Approximately-2.8-Million 2 http://www.smithersapex.com/news/2015/february/coronary-artery-disease-to-drive-$22-5-billion-mar
Contact Information Thomas Ichim, Ph.D President and CEO Viera BioScience 858 353 4303 [email protected]
Advertisement
"The AngioMune product has substantial potential as a tool for regenerative medicine given the ease of manufacturing, universal applicability and potential for superior biodistribution due to the smaller size of T regulatory cells compared to conventional stem cells," said Amit Patel, MS, MD, Head of Cardiothoracic Surgery at the University of Miami and Scientific Advisory Board member of Viera BioScience.
Advertisement
AngioMune is a cord blood derived product that has demonstrated ability to induce new blood vessel formation in animal models, a process called "angiogenesis." The market potential for angiogenesis stimulating products is in the billions of dollars due to potential for treatment of peripheral artery disease and coronary artery disease. Peripheral artery disease is estimated to have a market size in the U.S. of approximately $3 billion annually(1), and coronary artery disease of $12.2 billion(2).
"Having leveraged technology originating from the University of Utah, combined with our in-house advancements, we are proud to have advanced the AngioMune product from the bench to the bedside. I look forward to Dr. Ichim's presentation and announcement of our research, which has the potential to impact many patients who at present have no treatment options," said John Peck Jr., Chairman of Viera BioScience.
Event: 2017 Academy of Regenerative Practices Conference Presenter: Thomas Ichim, PhD, President and CEO of Viera BioScience: Stimulation of Angiogenesis by Angiostem T Regulatory Cells Where: Renaissance Hotel in Fort Lauderdale, Florida When: February 25th, 3:25 PM - 3:55 PM
1 http://www.businesswire.com/news/home/20101214006406/en/SAGE-GROUP-Reports-2010-Approximately-2.8-Million 2 http://www.smithersapex.com/news/2015/february/coronary-artery-disease-to-drive-$22-5-billion-mar
Contact Information Thomas Ichim, Ph.D President and CEO Viera BioScience 858 353 4303 [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/viera-bioscience-to-present-clinical-data-on-limb-ischemia-patients-treated-with-angiomune-cord-blood-t-regulatory-cell-product-300412485.html
SOURCE Viera BioScience Inc.
